SCHEMBL6090372

SCHEMBL6090372

CCC(O)(CC)c1ccc2sc(N)nc2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 3/20 0.48
NOS1 P29475 3/20 0.48
NOS2 P35228 3/20 0.48
SMN1; SMN2 Q16637 3/20 0.45
RAB9A P51151 3/20 0.45
SCN4A P35499 2/20 0.45
NPC1 O15118 2/20 0.45
EPHX2 P34913 1/20 0.45
PIK3CD O00329 2/20 0.44
PIK3CA P42336 2/20 0.44
PIK3CB P42338 2/20 0.44
PIK3CG P48736 2/20 0.44
CYP3A4 P08684 3/20 0.44
ALDH1A1 P00352 2/20 0.44
TP53 P04637 2/20 0.44
TSHR P16473 2/20 0.44
HSD17B10 Q99714 1/20 0.42
FTO Q9C0B1 1/20 0.42
MAPT P10636 1/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6089162 0.88 SCN4A (0.60) NOS3NOS1NOS2SMN1; SMN2RAB9A
SCHEMBL20049733 0.83 RAB9A (0.46) NOS3NOS1NOS2SMN1; SMN2RAB9A
SCHEMBL6088891 0.83 HSD17B10 (0.54) SMN1; SMN2RAB9ANPC1ALDH1A1TP53
SCHEMBL6089178 0.82 KMT2A (0.42) SMN1; SMN2HSD17B10DYRK1A
SCHEMBL179523 0.79 SCN4A (0.51) NOS3NOS1NOS2SMN1; SMN2RAB9A
SCHEMBL30261092 0.76 SCN4A (0.75) SMN1; SMN2RAB9ASCN4ANPC1EPHX2
SCHEMBL1913811 0.76 SCN4A (0.75) SMN1; SMN2RAB9ASCN4ANPC1EPHX2
SCHEMBL6089365 0.75 DYRK1A (0.70) SMN1; SMN2RAB9ANPC1CYP3A4HTT
Hydrochloric Acid SCHEMBL9362913 0.74 SCN4A (0.73) SMN1; SMN2RAB9ASCN4ANPC1EPHX2
SCHEMBL240595 0.72 SMN1; SMN2 (0.75) NOS3NOS1NOS2SMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060235222-A1 Indole-derivative modulators of steroid hormone nuclear receptors ELI LILLY AND COMPANY (US) 2006-10-19 US disclosed
EP-1597254-A1 INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS Eli Lilly and Company (US) 2005-11-23 EP disclosed
WO-2004067529-A1 INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS ELI LILLY AND COMPANY (US) 2004-08-12 WO disclosed
WO-2004067529-A1 INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS ELI LILLY AND COMPANY (US) 2004-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060235222-A1 Indole-derivative modulators of steroid hormone nuclear receptors NR3C2, NR5A1, MC2R NOS3 983/4885NOS1 729/4885NOS2 747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.